Log In
Print this Print this


Also known as: B7-H3 x CD3 DART molecule

  Manage Alerts
Collapse Summary General Information
Company MacroGenics Inc.
DescriptionBispecific antibody against CD3 and B7-H3 (CD276) developed using Dual-Affinity Re-Targeting (DART) technology
Molecular Target CD3 ; B7-H3 (CD276)
Mechanism of ActionBispecific antibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat solid tumors
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today